home / stock / gthx / gthx quote
Last: | $4.62 |
---|---|
Change Percent: | -0.84% |
Open: | $4.81 |
Close: | $4.62 |
High: | $5 |
Low: | $4.61 |
Volume: | 1,545,795 |
Last Trade Date Time: | 05/13/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.62 | $4.81 | $4.62 | $5 | $4.61 | 1,545,795 | 05-13-2024 |
$4.77 | $4.99 | $4.77 | $5.2 | $4.7403 | 1,397,380 | 05-10-2024 |
$4.98 | $4.28 | $4.98 | $6.14 | $4.28 | 34,352,168 | 05-09-2024 |
$4.29 | $4.2 | $4.29 | $4.36 | $4.13 | 558,518 | 05-08-2024 |
$4.25 | $4.27 | $4.25 | $4.28 | $4.1201 | 361,967 | 05-07-2024 |
$4.27 | $4.55 | $4.27 | $4.6 | $4.27 | 484,599 | 05-06-2024 |
$4.49 | $4.56 | $4.49 | $4.7 | $4.48 | 574,426 | 05-03-2024 |
$4.44 | $4.13 | $4.44 | $4.51 | $4.13 | 730,959 | 05-02-2024 |
$4.13 | $3.52 | $4.13 | $4.24 | $3.52 | 1,006,483 | 05-01-2024 |
$3.77 | $3.71 | $3.77 | $3.8575 | $3.65 | 528,648 | 04-30-2024 |
$3.72 | $3.95 | $3.72 | $4.03 | $3.7 | 691,138 | 04-29-2024 |
$3.99 | $3.85 | $3.99 | $4.045 | $3.84 | 441,518 | 04-26-2024 |
$3.86 | $3.93 | $3.86 | $3.93 | $3.77 | 538,433 | 04-25-2024 |
$3.99 | $4.19 | $3.99 | $4.235 | $3.94 | 342,425 | 04-24-2024 |
$4.19 | $4.15 | $4.19 | $4.32 | $4.1 | 354,922 | 04-23-2024 |
$4.1 | $4.15 | $4.1 | $4.2 | $3.945 | 488,179 | 04-22-2024 |
$4.11 | $4.13 | $4.11 | $4.305 | $3.965 | 733,126 | 04-19-2024 |
$4.17 | $4.31 | $4.17 | $4.31 | $4.035 | 692,601 | 04-18-2024 |
$4.28 | $4.15 | $4.28 | $4.35 | $4.09 | 690,098 | 04-17-2024 |
$4.08 | $4.25 | $4.08 | $4.32 | $3.99 | 569,479 | 04-16-2024 |
News, Short Squeeze, Breakout and More Instantly...
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know: Accor...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...